+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroparesis Drugs Market - Global Forecast 2026-2032- Product Image
Gastroparesis Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Gastroparesis Drugs Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5924669
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gastroparesis Drugs Market is projected to reach USD 5.24 Billion in 2026. It is expected to continue growing at a CAGR of 7.27%, reaching USD 7.97 Billion by 2032.

Gastroparesis drugs address delayed gastric emptying and associated symptoms such as nausea, vomiting, early satiety, bloating, and abdominal discomfort. Treatment decisions are shaped by disease cause, symptom severity, nutritional status, comorbidities, safety considerations, and local regulatory access. The therapeutic landscape includes prokinetic approaches, antiemetic therapies, agents used for symptom relief, and interventions supporting patients whose oral intake is inadequate. Clinical management remains individualized because disease presentation and treatment response vary substantially.

Treatment Is Shifting Toward Multimodal, Patient-Centered Care

The landscape is moving from symptom suppression alone toward coordinated care that combines dietary modification, medication review, glycemic management where relevant, nutritional support, and specialist referral. Greater attention is being given to adverse-effect monitoring, treatment sequencing, and the needs of patients with refractory symptoms. Diagnostic confirmation, assessment of nutritional risk, and differentiation from functional or obstructive disorders remain important influences on therapy selection. Access to specialist services and approved treatment options continues to differ across health systems.

Artificial Intelligence Is Strengthening Diagnosis, Development, and Monitoring

Artificial intelligence can support gastroparesis care by identifying patterns in clinical records, assisting image and motility-test interpretation, and helping clinicians stratify patients according to symptom burden or nutritional risk. In drug development, machine-learning tools may improve trial recruitment, endpoint selection, protocol design, and analysis of patient-reported outcomes. Digital symptom diaries and remote monitoring can provide longitudinal evidence on treatment response. These applications require clinically representative datasets, transparent validation, privacy safeguards, and careful oversight to prevent algorithmic bias or unsupported treatment recommendations.

Regional Insights: Uneven Access and Different Care Pathways

North America generally benefits from advanced gastroenterology infrastructure, although affordability, insurance coverage, and specialist availability can affect treatment continuity. Europe combines established clinical networks with country-level differences in reimbursement, authorization, and access to motility testing. Asia-Pacific includes sophisticated specialist systems alongside substantial variation in diagnostic capacity and medicine availability. Latin America faces uneven access to specialist care, diagnostic services, and dependable medicine supply. In the Middle East, urban tertiary centers may provide advanced services while coverage remains less consistent across populations. Africa continues to face constraints involving diagnostic infrastructure, trained specialists, medicine availability, and continuity of care.

Group Insights: Regulatory and Economic Blocs Shape Access

ASEAN markets reflect differing regulatory procedures, health-system resources, and access to specialist gastroenterology services, making regional harmonization and local evidence important. BRICS countries span diverse disease burdens, healthcare infrastructures, and reimbursement environments, with local manufacturing and public-sector procurement influencing availability. The European Union benefits from shared regulatory structures while retaining national differences in reimbursement and clinical implementation. G7 systems often have stronger research and specialist capacity, but access and affordability challenges remain. GCC countries are characterized by concentrated advanced care in major centers and a need to address regional service disparities. NATO membership does not create a uniform medicines system, so national approval, procurement, and clinical-practice differences remain decisive.

Country Insights: Local Systems Determine Gastroparesis Drug Use

Australia and Canada combine established specialist care with geographic access challenges. Brazil and Mexico must navigate regional disparities in diagnosis, reimbursement, and medicine supply. China and India have large and diverse healthcare systems in which specialist concentration and differing public-private access influence care pathways. France, Germany, Italy, Spain, and the United Kingdom operate within mature European clinical environments, but approval, reimbursement, prescribing practice, and service organization differ by country. Japan and South Korea have advanced medical infrastructure, with local clinical practice and regulatory requirements shaping adoption. Russia’s treatment environment is influenced by domestic availability, procurement conditions, and access to specialized diagnostics. In the United States, care is supported by extensive specialist capacity, while insurance design, affordability, and variation in access can affect treatment persistence.

Actions for Leaders: Improve Evidence, Access, and Treatment Safety

Industry leaders should prioritize robust evidence that measures clinically meaningful outcomes, including symptom relief, nutritional status, gastric-emptying measures where appropriate, and patient quality of life. Development programs should use clearly defined patient subgroups and incorporate safety monitoring suited to each mechanism. Partnerships with clinicians and patient communities can improve trial feasibility and support adherence. Access strategies should account for country-specific approval, reimbursement, procurement, and diagnostic pathways rather than relying on a single global model. Digital tools and artificial intelligence should be introduced with prospective validation, cybersecurity controls, explainability, and human clinical oversight. Clear education for prescribers and patients is essential, particularly where treatment risks, contraindications, or monitoring requirements are substantial.

Research Methodology: Evidence-Based Synthesis of the Gastroparesis Drug Landscape

This executive summary uses a structured qualitative synthesis of established clinical, regulatory, healthcare-delivery, and technology considerations relevant to gastroparesis drugs. Analysis should draw on peer-reviewed literature, clinical guidelines, regulatory documents, pharmacovigilance sources, health-system publications, and validated patient-reported evidence. Findings are organized across treatment evolution, artificial intelligence, regions, economic and political groups, and specified countries. Claims should be cross-checked across independent authoritative sources, with attention to publication date, study design, population characteristics, endpoint definitions, and geographic applicability. No market estimates, market shares, forecasts, or company-specific assessments are used.

Conclusion: Better Outcomes Depend on Integrated, Evidence-Led Care

Gastroparesis drug management is being shaped by the need for individualized treatment, stronger safety oversight, better diagnostic differentiation, and more coordinated nutritional and specialist support. Regional and national differences in regulation, reimbursement, infrastructure, and clinical expertise will continue to influence access and treatment implementation. Artificial intelligence may improve research and monitoring, but its value depends on rigorous validation and responsible governance. Leaders that combine clinically relevant evidence, patient-centered design, reliable supply, and locally adapted access strategies will be better positioned to support safer and more consistent care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gastroparesis Drugs Market, by Drug Type
7.1. Introduction
7.2. Dopamine Antagonists
7.2.1. Cisapride
7.2.2. Domperidone
7.2.3. Metoclopramide
7.3. Motilin Receptor Agonists
7.3.1. Azithromycin
7.3.2. Erythromycin
7.4. Serotonin Receptor Agonists
7.4.1. Granisetron
7.4.2. Ondansetron
8. Gastroparesis Drugs Market, by Disease Type
8.1. Introduction
8.2. Diabetic Gastroparesis
8.3. Idiopathic Gastroparesis
8.4. Postsurgical Gastroparesis
9. Gastroparesis Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Transdermal
10. Gastroparesis Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care Settings
10.4. Hospitals
11. Gastroparesis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Gastroparesis Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Gastroparesis Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Gastroparesis Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. AbbVie Inc.
16.3. Amneal Pharmaceuticals, Inc.
16.4. ANI Pharmaceuticals, Inc.
16.5. AstraZeneca PLC
16.6. Atlantic Healthcare PLC
16.7. Bausch Health Companies Inc.
16.8. Bristol-Myers Squibb Company
16.9. Cadila Pharmaceuticals Limited
16.10. Cairn Diagnostics
16.11. Evoke Pharma, Inc.
16.12. GlaxoSmithKline PLC
16.13. Johnson & Johnson Services, Inc.
16.14. Kyowa Kirin International plc
16.15. Lupin Limited
16.16. Medtronic PLC
16.17. Neurogastrx, Inc.
16.18. Novartis AG
16.19. Pfizer, Inc.
16.20. Processa Pharmaceuticals, Inc.
16.21. Sanofi S.A.
16.22. Takeda Pharmaceutical Company Limited
16.23. Theravance Biopharma
16.24. Vanda Pharmaceuticals Inc.
16.25. Viatris Inc.
17. Key Experts
List of Figures
FIGURE 1. Global Gastroparesis Drugs Market, Years Considered for the Study
FIGURE 2. Global Gastroparesis Drugs Market, Research Design
FIGURE 3. Global Gastroparesis Drugs Market, Research Framework
FIGURE 4. Global Gastroparesis Drugs Market, Data Triangulation
FIGURE 5. Global Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gastroparesis Drugs Market Size, by Drug Type, 2025 vs 2032 (%)
FIGURE 7. Global Gastroparesis Drugs Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gastroparesis Drugs Market Size, by Disease Type, 2025 vs 2032 (%)
FIGURE 9. Global Gastroparesis Drugs Market Size, by Disease Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gastroparesis Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Gastroparesis Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gastroparesis Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Gastroparesis Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gastroparesis Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Gastroparesis Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gastroparesis Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Gastroparesis Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Gastroparesis Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Gastroparesis Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Gastroparesis Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Gastroparesis Drugs Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Gastroparesis Drugs Market Segmentation & Coverage
TABLE 2. Global Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 4. Global Dopamine Antagonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Dopamine Antagonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Dopamine Antagonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Cisapride Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Cisapride Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Cisapride Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Domperidone Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Domperidone Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Domperidone Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Metoclopramide Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Metoclopramide Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Metoclopramide Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Motilin Receptor Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Motilin Receptor Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Motilin Receptor Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Azithromycin Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Azithromycin Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Azithromycin Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Erythromycin Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Erythromycin Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Erythromycin Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Serotonin Receptor Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Serotonin Receptor Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Serotonin Receptor Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Granisetron Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Granisetron Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Granisetron Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Ondansetron Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ondansetron Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ondansetron Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 35. Global Diabetic Gastroparesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Diabetic Gastroparesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Diabetic Gastroparesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Idiopathic Gastroparesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Idiopathic Gastroparesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Idiopathic Gastroparesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Postsurgical Gastroparesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Postsurgical Gastroparesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Postsurgical Gastroparesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 45. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 65. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 81. North America Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. North America Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 83. North America Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 84. North America Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 85. North America Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 86. North America Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 87. North America Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 88. North America Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. North America Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 90. Latin America Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Latin America Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 92. Latin America Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 93. Latin America Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 94. Latin America Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 95. Latin America Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 96. Latin America Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 97. Latin America Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Latin America Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Europe Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Europe Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 101. Europe Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 102. Europe Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 103. Europe Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 104. Europe Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 105. Europe Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 106. Europe Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Europe Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. Middle East Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Middle East Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 110. Middle East Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 111. Middle East Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 112. Middle East Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 113. Middle East Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 114. Middle East Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. Middle East Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Middle East Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 117. Africa Gastroparesis Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Africa Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 119. Africa Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 120. Africa Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 121. Africa Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 122. Africa Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 123. Africa Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 124. Africa Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Africa Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 126. Global Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. ASEAN Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. ASEAN Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 129. ASEAN Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 130. ASEAN Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 131. ASEAN Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 132. ASEAN Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 133. ASEAN Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. ASEAN Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. ASEAN Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. GCC Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. GCC Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 138. GCC Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 139. GCC Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 140. GCC Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 141. GCC Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 142. GCC Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. GCC Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. GCC Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. European Union Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. European Union Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 147. European Union Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 148. European Union Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 149. European Union Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 150. European Union Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 151. European Union Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 152. European Union Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. European Union Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. BRICS Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. BRICS Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 156. BRICS Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 157. BRICS Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 158. BRICS Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 159. BRICS Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 160. BRICS Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. BRICS Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. BRICS Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. G7 Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. G7 Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 165. G7 Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 166. G7 Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 167. G7 Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 168. G7 Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 169. G7 Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. G7 Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. G7 Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. NATO Gastroparesis Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. NATO Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 174. NATO Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 175. NATO Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 176. NATO Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 177. NATO Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 178. NATO Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 179. NATO Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. NATO Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Global Gastroparesis Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. United States Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 183. United States Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 184. United States Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 185. United States Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 186. United States Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 187. United States Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 188. United States Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. United States Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. United States Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. Canada Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 192. Canada Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 193. Canada Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 194. Canada Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 195. Canada Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 196. Canada Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 197. Canada Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 198. Canada Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Canada Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Mexico Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 201. Mexico Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 202. Mexico Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 203. Mexico Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 204. Mexico Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 205. Mexico Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 206. Mexico Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Mexico Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Mexico Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Brazil Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 210. Brazil Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 211. Brazil Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 212. Brazil Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 213. Brazil Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 214. Brazil Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 215. Brazil Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 216. Brazil Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Brazil Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. United Kingdom Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 219. United Kingdom Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 220. United Kingdom Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 221. United Kingdom Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 222. United Kingdom Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 223. United Kingdom Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 224. United Kingdom Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 225. United Kingdom Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. United Kingdom Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 227. Germany Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 228. Germany Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 229. Germany Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 230. Germany Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 231. Germany Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 232. Germany Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 233. Germany Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 234. Germany Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Germany Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. France Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 237. France Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 238. France Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 239. France Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 240. France Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 241. France Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 242. France Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 243. France Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. France Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. Russia Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 246. Russia Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 247. Russia Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 248. Russia Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 249. Russia Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 250. Russia Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 251. Russia Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 252. Russia Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. Russia Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. Italy Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 255. Italy Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 256. Italy Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 257. Italy Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 258. Italy Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 259. Italy Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 260. Italy Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 261. Italy Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Italy Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 263. Spain Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 264. Spain Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 265. Spain Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 266. Spain Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 267. Spain Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 268. Spain Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 269. Spain Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 270. Spain Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. Spain Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. China Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 273. China Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 274. China Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 275. China Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 276. China Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 277. China Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 278. China Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 279. China Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. China Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. India Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 282. India Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 283. India Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 284. India Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 285. India Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 286. India Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 287. India Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 288. India Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. India Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 290. Japan Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 291. Japan Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 292. Japan Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 293. Japan Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 294. Japan Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 295. Japan Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 296. Japan Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 297. Japan Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. Japan Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Australia Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 300. Australia Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 301. Australia Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 302. Australia Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 303. Australia Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 304. Australia Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 305. Australia Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 306. Australia Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 307. Australia Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 308. South Korea Gastroparesis Drugs Market Size, 2017-2032 (USD Million)
TABLE 309. South Korea Gastroparesis Drugs Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 310. South Korea Gastroparesis Drugs Market Size, by Dopamine Antagonists, 2017-2032 (USD Million)
TABLE 311. South Korea Gastroparesis Drugs Market Size, by Motilin Receptor Agonists, 2017-2032 (USD Million)
TABLE 312. South Korea Gastroparesis Drugs Market Size, by Serotonin Receptor Agonists, 2017-2032 (USD Million)
TABLE 313. South Korea Gastroparesis Drugs Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 314. South Korea Gastroparesis Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 315. South Korea Gastroparesis Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 316. South Korea Gastroparesis Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 317. Global Gastroparesis Drugs Market Share, by Key Player, 2025
TABLE 318. Global Gastroparesis Drugs Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amneal Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Atlantic Healthcare PLC
  • Bausch Health Companies Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Cairn Diagnostics
  • Evoke Pharma, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Medtronic PLC
  • Neurogastrx, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Processa Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • Vanda Pharmaceuticals Inc.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 7.97 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global Gastroparesis Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Global Gastroparesis Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 117 Pages
  • Global
From
Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Gastroparesis Drug Market Outlook 2026-2034: Market Share, and Growth Analysis by Drug Class, Disease Type, End User - Product Image

Gastroparesis Drug Market Outlook 2026-2034: Market Share, and Growth Analysis by Drug Class, Disease Type, End User

  • Report
  • 160 Pages
  • Global
From
Diabetic Gastroparesis Epidemiology Forecast 2026-2035 - Product Image

Diabetic Gastroparesis Epidemiology Forecast 2026-2035

  • Report
  • 100 Pages
  • Global
From
Gastroparesis Drugs Market Report 2026 - Product Image

Gastroparesis Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Gastroparesis Drug Market

Gastroparesis Drug is a type of drug used to treat gastroparesis, a condition in which the stomach muscles are weakened and unable to properly move food through the digestive system. These drugs are used to reduce symptoms such as nausea, vomiting, bloating, and abdominal pain. Commonly prescribed drugs for gastroparesis include metoclopramide, domperidone, and erythromycin. Other drugs, such as prokinetics, may also be used to help improve gastric emptying. Gastroparesis Drug is a part of the larger Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal conditions. These drugs are used to reduce symptoms, improve digestion, and prevent further complications. Commonly prescribed drugs in this market include antacids, proton pump inhibitors, and laxatives. Some companies in the Gastroparesis Drug market include Novartis, GlaxoSmithKline, Pfizer, and Takeda. Other companies, such as Allergan, Merck, and AstraZeneca, also produce drugs for the treatment of gastroparesis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.